MedPal AI (MPAL)  said its wholly owned subsidiary, MedPal Limited, has been approved as an authorised purchaser of Eli Lilly pharmaceutical products in the United Kingdom.

The approval allows MedPal to purchase and dispense Eli Lilly’s medicines, including Mounjaro (tirzepatide), a glucagon-like peptide-1 (GLP-1) receptor agonist used in type 2 diabetes and weight management.

The company said Mounjaro is the UK’s leading weight loss medication, with around 79% of the UK GLP-1 market. It added that research indicates around ten times more people in the UK buy Mounjaro privately than receive it through the National Health Service (NHS), pointing to a large private prescribing opportunity.

MedPal also noted that Wegovy, which MedPal.clinic already supplies, represents 20% of the market. The company said access to both products should allow patients to choose their preferred GLP-1 option.

MedPal said the UK prescription weight loss medications market is forecast to grow from around £340 million in 2025 to £2 billion by 2033, and that an estimated 3.4 million people in the UK are eligible for tirzepatide treatment.

The company said dispensing will be handled from its robotic distribution centre in Swaffham, Norfolk, which it believes supports scalable fulfilment as demand grows.

MedPal AI’s CEO Jason Drummond said: "Securing direct supply rights with Eli Lilly, the manufacturer of the UK's leading weight loss medication, is an important milestone for MedPal AI. Access to Mounjaro strengthens our ability to serve patients through MedPal.clinic, where our AI triage technology connects individuals with appropriate clinical pathways for weight management. With our robotic dispensing facility in Swaffham, we are well positioned to meet growing patient demand."

View from Vox

Direct purchasing rights for Eli Lilly products look like a meaningful step for MedPal’s private weight management ambitions, particularly given the company’s focus on AI-led triage and its automated dispensing infrastructure. If MedPal can translate broader product access into higher patient throughput at MedPal.clinic, it may strengthen both growth visibility and competitive positioning in a rapidly expanding market.